EPC of the NHF hfafacebookinstagramtwitter

Research Grants

 

An important part of the Chapter’s mission is to support research and we are so fortunate to have incredible doctors doing amazing work in our coverage area. At this year’s Trick or Trot Family Walk, EPC awarded grants to the Hemophilia Treatment Centers at the Children’s Hospital of Philadelphia, the Hospital of the University of Pennsylvania, and Penn State Hershey Medical Center. The total amount was $55,000.


The research at CHOP is being conducted by Ben Samelson-Jones, MD, PhD. The project is entitled “Modified red blood cells as a novel therapeutic strategy for immune tolerance induction in hemophilia.” The objective is to use a novel approach that has been successful in autoimmune diseases to establish immune tolerance to clotting factors in hemophilia patients with inhibitors. This preclinical development would set the stage for clinical trials with a goal of providing a new therapeutic option to this patient population using their own red blood cells.


The project at Penn is being run by Allyson Pishko, MD and is entitled “The Effect of Obesity on Joint Outcomes, Prophylaxis Usage, and Quality of Life in Patients with Hemophilia.” She will assess if obesity is associated with increased annual joint bleed rates, pain, orthopedic surgery procedures, and impaired quality of life. If obesity is a significant risk factor for adverse joint outcomes in patients with hemophilia as suspected, her long-range plan would be to conduct further studies assessing weight-loss interventions specific to patients with hemophilia.


The research at Penn State Hershey Medical Center is being conducted by Matthew Evans, MD. The project is entitled “Exploratory Study of Inhibitor Development in non-severe Hemophilia A Patients Utilizing a Novel Screening Test.” His overall objective is to evaluate the potential for improvement in screening and recognition of inhibitors in persons with non-severe hemophilia A, and to further advance his understanding of inhibitor development in this patient population.